Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...

Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

LONDON--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London ...

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in asymptomatic severe aortic ...

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences (NYSE ...

Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its core product, the Transcatheter Aort ...

LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit ... the Company's growth was at risk of decelerating; (3) the Company's "patient activation activities" failed to ...